NTB-928 in relapsed or refractory ovarian cancer
Official title: A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma
Run by 92Bio, Inc. · NCT07690189 · Data updated 2026-11-12
This early-phase study tests NTB-928 in adult women whose ovarian cancer has come back or stopped responding to treatment to see if it is safe, how the drug behaves in the body, and whether it shows any early anti-cancer activity.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 90 (estimated) |
| Sponsor | 92Bio, Inc. Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Birmingham, Alabama and 3 other locations) |
| Status | Recruiting |
| Started | June 29, 2026 |
| Main results expected | June 2028 |
| Study ends | February 2029 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT07690189 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with confirmed relapsed or refractory ovarian cancer of specified histologies who have exhausted standard treatments and can consent.
✕Probably not a fit
Patients with cancers not responsive to NTB-928, or those who do not experience early activity, may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1 interventional trial evaluating NTB-928 in adults with relapsed or refractory ovarian cancer. The study will determine safety and tolerability, study how NTB-928 is processed and distributed in the body, and explore immune responses and early signs of anti-cancer activity at different dose levels. Eligibility includes adults with confirmed ovarian cancer subtypes who have exhausted standard therapies and can provide informed consent. Exclusions include another active cancer or recent use of other investigational drugs. The trial is led by TeneoSeven, with sites at three academic centers in the U.S.
Why it matters
Potential benefit: Participants may receive early information on NTB-928’s safety and potential signs of anti-tumor activity.
How similar studies have gone: Early-phase studies of similar novel therapies in ovarian cancer have shown variable safety and preliminary activity; this exact agent is being evaluated for novelty and potential activity.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years or older * Have a confirmed diagnosis of ovarian cancer, including high-grade serous, high-grade endometrioid, low-grade serous, or clear cell ovarian cancer, or carcinosarcoma of the ovary. Patients with mucinous carcinoma are not eligible. * Have relapsed or refractory ovarian cancer and have already received standard treatments known to provide benefit; participants are eligible if they have platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer (with clearly documented ineligibility for further platinum chemotherapy). * Are able to understand the study requirements and are willing to provide written informed consent * Are willing to use effective birth control during the study and for a period after the last dose of study treatment, if of childbearing potential Exclusion Criteria: * Have another active cancer that could interfere with assessment of this study treatment * Have received another investigational drug or certain cancer treatments within a recent period before starting this study * Are pregnant or breastfeeding
Where it's running
-
The University of Alabama
Birmingham, Alabama, United States Recruiting -
University of Nebraska Medical Center
Omaha, Nebraska, United States Recruiting -
START Northwell, LLC
Lake Success, New York, United States Recruiting -
Start Ccbd, Llc
Fort Worth, Texas, United States Recruiting
Study contacts
- Study coordinator: Clinical Trial Information
- Email: clinicaltrial@92biotech.com
- Phone: 510-392-0929
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Different doses of BI 3820768 for adults with advanced germ cell, endometrial, or ovarian cancer
This trial tests increasing doses of BI 3820768, an immune-stimulating injection, in adults with advanced, relapsed, or refractory germ cell, endometrial, or ovarian cancer to find a tolerable dose that may shrink tumors.
-
Using MUC1-activated T cells to treat resistant ovarian cancer
This study is testing a new treatment using specially designed immune cells to see if they can help people with tough-to-treat ovarian cancer feel better and improve their health.
-
CPI-613 combined with hydroxychloroquine and chemotherapy for advanced solid tumors
This study is testing a new combination of treatments, including CPI-613 and hydroxychloroquine, to see if it can help people with advanced solid tumors that haven't improved with other chemotherapy.
-
Combining ONC201 with Paclitaxel for Ovarian Cancer Treatment
This study is testing if combining a new drug called ONC201 with paclitaxel can help people with hard-to-treat ovarian cancer feel better and live longer.
-
Evaluating NKT3964 for Adults with Advanced Solid Tumors
This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.